Stockscreener 앱 받기
35.97
0.91%
-0.33
시간 외 거래:
35.28
-0.69
-1.92%
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
VTV Therapeutics (VTVT) reports $27M 2025 net loss amid cadisegliatin advancements - MSN
vTv Therapeutics (VTVT) Reports $27M 2025 Net Loss Amid Cadisegliatin Advancements - Yahoo Finance
Wall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to Trade - Yahoo Finance
vTv Therapeutics to Participate in the 38th Annual ROTH Conference - The Manila Times
VTv Therapeutics to Participate in the 38th Annual ROTH Conference - marketscreener.com
Biotech developing oral type 1 diabetes drug joins ROTH investor event - Stock Titan
Baker BROS. Advisors LP Has $3.46 Million Holdings in vTv Therapeutics Inc. $VTVT - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Upgraded at Evercore - MarketBeat
Wall Street Zen Upgrades vTv Therapeutics (NASDAQ:VTVT) to "Hold" - MarketBeat
HC Wainwright Raises Earnings Estimates for vTv Therapeutics - Defense World
HC Wainwright Brokers Increase Earnings Estimates for VTVT - Defense World
HC Wainwright Forecasts Higher Earnings for vTv Therapeutics - MarketBeat
This Jabil Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Oxford BioMedica (OtherOXBDF) - The Globe and Mail
Evercore ISI initiates vTv Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Evercore ISI Initiates vTv Therapeutics at Outperform With $44 Price Target - marketscreener.com
Evercore ISI Initiates Coverage on VTVT with Outperform Rating | VTVT Stock News - GuruFocus
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT) - The Globe and Mail
Research Analysts Set Expectations for VTVT Q1 Earnings - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Share Price Crosses Below 50-Day Moving AverageShould You Sell? - MarketBeat
vTv Therapeutics (VTVT) Projected to Post Earnings on Thursday - MarketBeat
Avoiding Lag: Real-Time Signals in (VTVT) Movement - Stock Traders Daily
BTIG Maintains Buy on vTv Therapeutics Inc (VTVT) March 11, 2026 - Meyka
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained By Investing.com - Investing.com Canada
VTVT: BTIG Reiterates Buy Rating with Unchanged Price Target | V - GuruFocus
BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained - Investing.com
vTv Therapeutics 2025 – Pipeline, Clinical Trials, and Patent Portfolio Overview - Minichart
vTv Therapeutics price target raised to $55 from $35 at Alliance Global - TipRanks
VTv Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway - TipRanks
vTv Therapeutics 2025 10-K: $0.0M Revenue, $(26.97)M Net Loss - TradingView
VTv Therapeutics: Fourth Quarter Earnings Overview - Bitget
vTv Therapeutics Inc 預計每股虧損 81 美分財報前瞻 - TradingView
VTV Therapeutics (VTVT) Quarterly & Annual Financial Results 2026News and Statistics - IndexBox
vTv Therapeutics (NASDAQ: VTVT) highlights cadisegliatin Phase 3 and new funding - Stock Titan
VTVT Stock Bolstered by Strong Financials and Strategic Advances - GuruFocus
vTv Therapeutics (VTVT) spotlights Phase 3 cadisegliatin and cash runway - Stock Titan
vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09) - TipRanks
vTv Therapeutics (VTVT) boosts cash, advances Phase 3 CATT1 trial - Stock Titan
vTv Therapeutics Q4 net loss widens on higher expenses - TradingView
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Weekly Voice
Diabetes drug developer vTv secures $20M as key trial enrollment nears - Stock Titan
Vtv Therapeutics: Capital Efficiency and Clinical Catalysts Under Scrutiny - AD HOC NEWS
Aug Shorts: Will vTv Therapeutics Inc outperform the market in YEAREarnings Risk Report & Verified Technical Trade Signals - baoquankhu1.vn
How vTv Therapeutics Inc. (5VT0) stock correlates with oil marketsJuly 2025 WrapUp & Fast Entry High Yield Tips - Naître et grandir
vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737 - Yahoo Finance
12 Most Promising Micro-Cap Stocks According to Analysts - Insider Monkey
Discipline and Rules-Based Execution in VTVT Response - Stock Traders Daily
VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst - Seeking Alpha
VTVT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 61.2% in February - Defense World
VTVT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
VTVT PE Ratio & Valuation, Is VTVT Overvalued - Intellectia AI
vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength - TipRanks
vTv Therapeutics posts updated investor presentation highlighting Phase 3 cadisegliatin readout and $118.5M liquidity - TradingView
vTv Therapeutics (VTVT) spotlights cadisegliatin Phase 3 and cash runway - Stock Titan
VTVT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):